Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,107 public trials 2,039 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

NCT02576496

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Cutaneous T Cell Lymphoma, +23 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • Mayo Clinic Cancer Center Jacksonville, Florida, United States
  • Columbia University Medical Center New York, United States
  • University Hospitals Cleveland Seidman Cancer Center Cleveland, Ohio, United States
View all 18 locations
View Trial Details
Completed

A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)

NCT04840680

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Hallym University Sacred Heart Hospital Anyang, South Korea
  • SOONCHUNHYANG UNIVERSITY HOSPITAL Bucheon Bucheon-si, South Korea
  • Inje University Busan Paik Hospital Busan, South Korea
  • Pusan National University Hospital Busan, South Korea
View all 20 locations
View Trial Details
Completed

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

NCT01523977

Conditions
Acute Lymphoblastic Leukemia, Disease Attributes, Hematologic Diseases, +13 more
Locations
  • UCSF San Francisco, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • Children's Healthcare of Atlanta Atlanta, Georgia, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States
View Trial Details
Completed

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

NCT01660451

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • Birmingham, Alabama, United States
  • Gilbert, Arizona, United States
  • Anaheim, California, United States
  • Aurora, Colorado, United States
View all 102 locations
View Trial Details
Completed

Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

NCT01472562

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • University of Chicago Chicago, Illinois, United States
  • Weill Cornell Medical College New York, United States
  • University of Pennsylvania Philadelphia, Pennsylvania, United States
View Trial Details

Related conditions